Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-66nw2 Total loading time: 0.231 Render date: 2021-12-06T09:58:43.926Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Diagnostics of the AML with immunophenotypical data

Published online by Cambridge University Press:  15 May 2008

A. Plesa
Affiliation:
Service d'Hématologie clinique, Hospices Civils de Lyon, 69003 Lyon, France
G. Ciuperca
Affiliation:
Université de Lyon, Université Lyon 1, CNRS UMR 5208 Institut Camille Jordan F - 69200 Villeurbanne Cedex, France
V. Louvet
Affiliation:
Université de Lyon, Université Lyon 1, CNRS UMR 5208 Institut Camille Jordan F - 69200 Villeurbanne Cedex, France
L. Pujo-Menjouet*
Affiliation:
Université de Lyon, Université Lyon 1, CNRS UMR 5208 Institut Camille Jordan F - 69200 Villeurbanne Cedex, France
S. Génieys
Affiliation:
Université de Lyon, Université Lyon 1, CNRS UMR 5208 Institut Camille Jordan F - 69200 Villeurbanne Cedex, France
C. Dumontet
Affiliation:
Service d'Hématologie clinique, Hospices Civils de Lyon, 69003 Lyon, France
X. Thomas
Affiliation:
Service d'Hématologie clinique, Hospices Civils de Lyon, 69003 Lyon, France
V. Volpert
Affiliation:
Service d'Hématologie clinique, Hospices Civils de Lyon, 69003 Lyon, France
Get access

Abstract

Patients with acute myeloblastic leukemia (AML) are divided according to the French American British (FAB) classification into eight subgroups (M0 to M7) on the basis of their degree of maturation/differentiation. However, even if immunophenotypical characterization by flow cytometry is routinely used to distinguish between AML and acute lymphoblastic leukemia (ALL), it is not yet well established for the identification within the AML subgroups. Here we show that certain subgroups of AML can be identified with a good accuracy (80% of the patients we analyzed) by means of the expression of specific markers.

Type
Research Article
Copyright
© EDP Sciences, 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Diagnostics of the AML with immunophenotypical data
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Diagnostics of the AML with immunophenotypical data
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Diagnostics of the AML with immunophenotypical data
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *